Over the past 5+ years the activities related to this new cryoablation technology has been funded by the Founders as well as by accredited investors through a Series A Preferred round of financing. The Company is in the process of raising an additional $12 million of capital through a Series B Preferred round of financing. For additional information please contact the Company.